D.C. Circuit: Grant Of Exclusive Patent License Not Anticompetitive
WASHINGTON, D.C. — A panel of the District of Columbia Circuit U.S. Court of Appeals ruled Aug. 25 that allegations by Federal Trade Commission drugmakers violated antitrust law by the terms...To view the full article, register now.
Already a subscriber? Click here to view full article